Treatments for Parkinson disease--past achievements and current clinical needs.
about
Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-AnalysisRotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptorsNeuromodulation: selected approaches and challengesNew MRI Biomarkers Advance the Characterization of Parkinson Disease.Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.Versatile somatic gene transfer for modeling neurodegenerative diseases.Deep brain stimulation: technology at the cutting edgeFocus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.Five-year follow-up of 23 asymmetrical Parkinson's disease patients treated with unilateral subthalamic nucleus stimulation.Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease.Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.Stem cell technology for neurodegenerative diseases.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: an H(2)(15)O PET study.Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's diseaseEffect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson's Disease.Dynamic DNA Methylation Regulates Levodopa-Induced DyskinesiaRecognition and management of Parkinson's disease during the premotor (prodromal) phase.Molecular pathogenesis of Parkinson disease: insights from genetic studies.Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease.The incidence of deep brain stimulator hardware infection: the effect of change in antibiotic prophylaxis regimen and review of the literature.Moving forward: advances in the treatment of movement disorders with deep brain stimulation.Hippocampal neuronal metal ion imbalance related oxidative stress in a rat model of chronic aluminum exposure and neuroprotection of meloxicam.Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.The use of subcutaneous scopolamine as a palliative treatment in Parkinson's disease.String Vessel Formation is Increased in the Brain of Parkinson Disease.Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.Multiscale entropy analysis of electroencephalography during sleep in patients with Parkinson disease.'Being in it together': living with a partner receiving deep brain stimulation for advanced Parkinson's disease--a hermeneutic phenomenological study.Vascular degeneration in Parkinson's disease.Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.Tetrahydroisoquinolines functionalized with carbamates as selective ligands of D2 dopamine receptor.Dysregulation of BET proteins in levodopa-induced dyskinesia.PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
P2860
Q21131738-24E62737-D547-4508-A431-6FA58DBD12C4Q28250152-A176CFA2-3BF7-44F3-8EE6-9028DD1CAE72Q30443637-AD8CF235-9499-463B-A7F0-47508935D7DCQ30835312-D6E811DC-F3FD-46FF-9F8F-62DEA2731199Q33785397-23019B27-61FA-4049-B5A9-FA2C5244D7C7Q33870490-DC3D9130-A6AD-4B94-BBC0-543D8D8A4201Q34285870-146D8293-D7E1-477D-B70F-0E497CBD2816Q34508149-634FE018-4149-46AE-8AF5-F5A6C63CFE89Q34793270-9A89F4D9-43A9-4253-82FB-6F799AAE16A1Q35020852-6C1CC44F-2896-4CF8-AF2A-124B2CBDBF07Q35036220-4FA04326-FDF6-4691-BF38-4186480A9566Q35142884-476D4B07-C250-4035-931D-5823D06225A6Q35188119-04C1F7D2-0330-4DE6-8439-F5C428AA65B2Q35224202-155E9C73-E614-4595-A833-EB31065547D4Q35264378-11811B37-6259-4046-9684-3E11EC522DC7Q35690145-77AA5BF6-92BD-4293-A623-CCE0C65ABA43Q35748449-E28AA2A5-A754-45B1-AFAA-48F0C4064AB1Q35863280-735E2881-7BC9-4E7E-A03F-260EDAFBDF12Q35999154-922F8E53-2622-4759-A40E-4AD82EF7C361Q37241754-A46EF75B-F68C-473A-8D5A-B5A5FF86461FQ37507968-C614A98B-6937-499E-A3FB-3D9FC0A0109EQ37561699-6A2F60B0-53AB-4068-B457-09DEE1D6A86EQ37767768-62409852-B937-450C-904C-186BF269173DQ37866328-51E49A3E-1C13-4DC0-B951-2A4CA8AF4E5AQ37956311-EBAFCAE8-007A-4BA7-8854-9888C9900DB5Q38897776-01D0360C-7CF0-4565-A154-E41693FE607DQ38925121-A7371D35-5479-494B-9CB0-21ACDBBCEBD1Q39280456-18012079-36F9-451D-B416-2650638AB980Q40458640-3C31BF1F-9EDC-48DE-9030-CCE52617DC0EQ42372900-B0D5B4D3-8DFF-4FDF-856D-43BC9A2B20EDQ42484958-66D9B040-A592-4B03-AB5F-B5B667F5B559Q43290028-24252034-382B-425A-965F-1F64E32145BEQ44212444-2ABE7431-54F4-4172-9A47-FB548704EF47Q44235563-968CA32F-1218-4D61-8D6F-CCC72CFB8FB4Q44618130-2C1ECCA1-6757-470A-9BC5-5E8EA80653DFQ47256703-9D5ACAF8-F49C-4954-AB68-C4BC62F406F2Q48945974-722D9A8A-7A07-40EE-90EF-FF0B6B816A85Q50230042-F156629F-241B-4755-BE0B-A9122EEBDF68Q50592833-10DF6285-AAB1-49F1-8D95-915003D2914FQ58587583-E70A0310-B069-4980-937B-27E2F519057A
P2860
Treatments for Parkinson disease--past achievements and current clinical needs.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatments for Parkinson disease--past achievements and current clinical needs.
@ast
Treatments for Parkinson disease--past achievements and current clinical needs.
@en
Treatments for Parkinson disease--past achievements and current clinical needs.
@nl
type
label
Treatments for Parkinson disease--past achievements and current clinical needs.
@ast
Treatments for Parkinson disease--past achievements and current clinical needs.
@en
Treatments for Parkinson disease--past achievements and current clinical needs.
@nl
prefLabel
Treatments for Parkinson disease--past achievements and current clinical needs.
@ast
Treatments for Parkinson disease--past achievements and current clinical needs.
@en
Treatments for Parkinson disease--past achievements and current clinical needs.
@nl
P1433
P1476
Treatments for Parkinson disease--past achievements and current clinical needs.
@en
P304
P356
10.1212/WNL.0B013E31819908CE
P407
P433
P50
P577
2009-02-01T00:00:00Z